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Abstract
Anaplastic thyroid cancer (ATC) is a rare disease with an incidence of less than three cases per million of
habitants in western countries. ATC accounts for 1-10% of all tumors derived from the thyroid gland.
Classic chemotherapy approach based on platinum and anthracyclines regimens have been considered
standard for the last decades. Novel multitarget agents have shown promising responses; however, no
positive randomized clinical trials are available up to now. To our knowledge, the case we are presenting
here is the first reported case showing clinical and visual activity using sunitinib as a salvage treatment in
an ATC patient who was not fit to receive systemic chemotherapy treatment.
Keywords: Anaplastic thyroid cancer, angiogenesis, sunitinib
INTRODUCTION
Thyroid cancer is the most common endocrine malignancy.[1] More than 90% of all thyroid cancers derive
from the thyroid follicular cells, including papillary thyroid cancers (PTC), follicular thyroid cancers
(FTC), or Hόrthle cell carcinomas. Anaplastic thyroid cancers (ATC) are estimated to comprise 1.3-9.8%
of thyroid malignancies and they usually arise from pre-existing PTC or FTC.[2] Despite more aggressive
systemic therapies and better surgical techniques, survival of patients with ATC has barely changed in
decades and median overall survival ranges from 5 to 7 months with only 20% of patients expected to be
alive 1 year after diagnosis.[2] Therefore, new drugs are urgently needed for these patients.
A greater understanding in the molecular biology of thyroid cancer highlights the significance of several
gene mutations of main intracellular pathways related with the pathogenesis of these tumors, such as p53
(55%), RAS (22%), BRAF (26%), β-catenin (38%), PI3K (17%), and PTEN (12%).[3] Additionally,
amplification in gene copy number of epidermal growth factor receptor (EGFR), vascular endothelial
growth factor receptor (VEGFR-1, and -2), platelet derived growth factor (PDGFR-α and -β), stem cell
factor receptor (c-Kit), pyruvate dehydrogenase kinase (PDK1), protein kinase B AKT1, and hepatocyte
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angiogenesis plays a key role in tumor proliferation and dissemination of ATCs.[4] We currently have
several multi-targeted tyrosine kinase inhibitors that block receptors involved not only in tumor growth but
also in angiogenesis.
As far as we know, the case we are presenting here is the first reported case showing clinical and visual
activity with sunitinib as a salvage treatment in an ATC patient.
CASE PRESENTATION
A 79-year-old man with a medical history of hypertension and diabetes was diagnosed with a localized
papillary thyroid carcinoma was admitted at the Ramón y Cajal University Hospital Madrid (Spain). There
was no evidence of distant metastasis at diagnosis. The patient underwent a total thyroidectomy and a
suspicious right-cervical lymph node was also resected. The pathological stage after surgery was pT2
pN1b M0. Following surgery, thyroid ablation therapy with 150 mCi of radioactive iodine ( I) was
given. One year later, although no evidence of distant spread of the disease was observed in a whole body
scan, serum thyroglobulin levels were 24 ng/ml (normal range <3 ng/mL), despite suppressive thyroxin
therapy. Therefore, a second course of I was administered, achieving a total dose of 350 mCi of I.
Two years after surgery, during a follow-up visit, it was noted that the patient had recurrence of his disease,
due to a rapid appearance of a midline hard, rigid, painful, and violet neck mass, just below the scar of
previous thyroidectomy, and bilateral cervical lymph nodes [Figure 1a] together with moderate dyspnoea.
Macroscopic neck mass size was initially measured as 6.5 × 3.5 cm. Multiple and bilateral lung metastasis
were detected in a computer tomography (CT) scan. Fine needle aspiration cytology of the thyroid mass
revealed anaplastic thyroid carcinoma cells. Based on recent reported data with multi-target tyrosine kinase
inhibitors in iodine-refractory thyroid cancer patients added to the age, performance status, and
comorbidities of the patient, we decided to start treatment with sunitinib (SUTENT , Pfizer Inc, NY) as a
single agent under “off-label” use request from a clinical trial. The patient signed the appropriate informed
consent and local legal procedures were followed. Sunitinib was administered orally at 50 mg per day for 4
weeks followed by 2 weeks of rest. A weekly follow up was undertaken and at the first week of treatment
a reduction in neck tumor bulk was noted (6.0 × 3.0 cm) with clinical improvement of pain and less violet
neck mass [Figure 1b]. After the start of the treatment for 4 weeks the tumor mass clearly showed a
reduction in size (3.0 × 1.5 cm) and skin color was almost normal [Figure 1c]. The patient reported neither
pain nor dyspnoea at this time and Eastern Cooperative Oncology Group (ECOG) performance status was
0. After the end of second cycle, 12 weeks from the beginning of treatment, a complete macroscopic
response of the ATC in the neck was achieved [Figure 1d] and it was maintained for 8 more weeks.
Tolerability of sunitinib was acceptable with grade 2 asthenia and grade 2 neutropenia with only one week
of rest needed to recover after third cycle. However, response in tumor size over neck mass did not
correlate with lung metastasis shrinkage that were stable after 12-20 weeks of treatment. Unfortunately, the
patient died as a result of a massive upper gastrointestinal bleeding 5 months after the start of sunitinib
treatment and while the patient was still on treatment.
CONCLUSION
There is a lack of large clinical trials addressing the best treatment option for disseminated ATC patients. It
has been reported recently, the largest ever randomized trial in ATC that compared carboplatin plus
paclitaxel given for six cycles with or without CA4P (a vascular disrupting agent). Despite the fact that
only 80 of 180 planned patients were recruited (due to a slow recruitment rate), a strong trend in improved
overall survival was observed; 5.2 months versus 4.0 months for the CA4P and control arm respectively
(Hazard Ratio 0.95:95% CI, 0.38-1.10).[5] Nagaiah et al. reported the treatment of 16 metastatic ATC
patients with sorafenib.[6] Two (13%) out of 15 evaluable patients achieved partial response by Response
Evaluation Criteria In Solid Tumors (RECIST) criteria, however, median progression free survival was
only 1.9 months (95% CI: 1.7-4.1) and median overall survival was 3.9 months (95% CI: 2.7-7.1). Our
group tested sorafenib activity in patients with metastatic thyroid carcinomas including three patients with
ATC. One out of 3 (33%) patients achieved an objective partial response with a median overall survival of
5 months.[7] Axitinib is a novel multitarget agent with a more selective kinase inhibition profile against
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controlled phase 2 trial had ATC histology. One of these two patients achieved partial response
radiologically and the authors concluded that the activity of axitinib was independent of tumor histology.
[8]
Sunitinib is an oral multitargeted inhibitor of several tyrosine kinase receptors including glial cell line-
derived neurotrophic factor (RET) and angiogenesis-related VEGFRs (-1, -2 and -3) and PDGFRs (-α and
-β) receptors.[9] Up to five non-controlled trials have been reported up to now with sunitinib as a single
agent treatment of differentiated thyroid cancer (DTC) and/or medullary thyroid cancer (MTC) thyroid
cancers.[10,11,12,13,14] The largest study was conducted by Cohen et al. in 43 patients, mostly DTC.
Clinical benefit rate, including complete and partial responses plus disease stabilizations was 81% in those
patients with DTC histology.[11] Ravaud et al. conducted a trial in 12 patients with DTC and 8 patients
with MTC.[13] The clinical benefit was 75-100% in DTC and MTC respectively. Recently, Carr et al.
reported a study that included 35 patients (28 DTC, 7 MTC).[10] Objective responses were observed in 11
patients (31%; 95 CI: 16-47%) including one patient who achieved a complete response. The median time
to tumor progression was 12.8 months (95% CI, 8.9 months-not reached). Unfortunately, none of the
recruited patients in these trials treated with sunitinib presented ATC histologic subtype and thus the effect
that this drug may have on the treatment of these patients remains elusive.
To our knowledge, this is the first reported case showing clinical activity with sunitinib in ATC patients.
The impressive response induced in neck tumor mass with no impact in distant metastases suggests that
there may be different genetic features between primary and secondary lesions. Although not frequent, it
has been largely described as the existence of paradoxical responses between the primary tumor and the
distant metastasis. Tumor heterogeneity and the accumulation of molecular aberrations when tumor
progresses make that metastasis may become more resistance to local and systemic treatment than the
primary tumors.[15]
Despite the aggressive behavior of ATC, we have seen a rapid response of a targeted agent showing the
efficacy of these drugs in this setting. However, effective predictive biomarkers are needed, especially in
this scenario where second options are rarely available due to the dramatic outcome of these patients.
The toxicity profile of targeted therapies has been generally described as favorable when compared with
classical cytotoxic drugs, although, potentially fatal side effects have been reported, mainly related with
anti-angiogenic effects and cardiovascular toxicity.[16]
Patients with tumors with an undifferentiated histology are more difficult to recruit in trials and thus we
cannot extrapolate results from differentiated samples due to differences in tumor biology. However, there
is an increasing body of evidence showing that counteracting angiogenesis may become a valid strategy in
aggressive thyroid carcinomas. Further prospective and randomized trials are needed to evaluate the
efficacy and also the quality of life of patients treated with novel oral targeted agents when compared with
the classical chemotherapy-based approach of doxorubicin, platinum, and combinations of taxanes.
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Figure 1
Dramatic objective response with over secondary anaplastic thyroid cancer developed under the scarce of a previous
thyroidectomy of a differentiated tumor, (a) tumor before starting sunitinib, (b and c) response induced by sunitinib after 1
and 4 weeks of systemic treatment with sunitinib respectively, (d) a complete response after 2 cycles (sunitinib given at 50
mg/day for 4 weeks followed by 2 weeks of rest per cycle)
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